
Barbara Pasculli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3991561/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ALYREF, a novel factor involved in breast carcinogenesis, acts through transcriptional and post-transcriptional mechanisms selectively regulating the short NEAT1 isoform. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	17
2	Combined analysis of miR-200 family and its significance for breast cancer. Scientific Reports, 2021, 11, 2980.	1.6	22
3	Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors. Frontiers in Oncology, 2020, 10, 1415.	1.3	31
4	Carbonic Anhydrase XII Expression Is Modulated during Epithelial Mesenchymal Transition and Regulated through Protein Kinase C Signaling. International Journal of Molecular Sciences, 2020, 21, 715.	1.8	12
5	Abstract 1422: Clinical association of miR-155-5p with breast cancer and its relevance for treatment with PARP inhibitors. , 2020, , .		0
6	Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel. Scientific Reports, 2019, 9, 14913.	1.6	19
7	MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors. Breast Cancer Research, 2019, 21, 20.	2.2	52
8	Can Epigenetics of Endothelial Dysfunction Represent the Key to Precision Medicine in Type 2 Diabetes Mellitus?. International Journal of Molecular Sciences, 2019, 20, 2949.	1.8	27
9	Abstract 4904: High levels of microRNA-210-3p are associated with increased risk of disease progression in breast cancer patients treated with docetaxel. , 2019, , .		0
10	Abstract 4904: High levels of microRNA-210-3p are associated with increased risk of disease progression in breast cancer patients treated with docetaxel. , 2019, , .		0
11	Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine. Seminars in Cancer Biology, 2018, 51, 22-35.	4.3	115
12	Predictive Value of Epigenetic Signatures. , 2018, , 275-311.		0
13	Abstract 5394: Initial results from TRANSCAN ERA-NET BREMIR project: MicroRNAs expression profiling for identification of breast cancer patients at high risk to develop distant metastases. , 2018, , .		0
14	N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome Biology, 2017, 18, 98.	3.8	97
15	Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients. Scientific Reports, 2017, 7, 45283.	1.6	45
16	Abstract 4734: miR-9-5p expression in breast cancer correlates with hormone receptor status and affects patients survival. , 2017, , .		1
17	Evaluation of pre-analytical procedures for the detection of BRAF V600 mutations in melanoma patients: comparison between Sanger sequencing and Competitive allele-specific TaqMan PCR (Cast-PCR). European Journal of Cancer, 2016, 61, S127-S128.	1.3	1
18	Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Molecular Cell, 2016, 61, 520-534.	4.5	142

BARBARA PASCULLI

#	Article	IF	CITATIONS
19	Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients. Scientific Reports, 2015, 5, 18592.	1.6	27
20	Abstract 3977: Evaluation of miR10b and miR9 expression in breast cancer and correlations with distant metastases development. , 2015, , .		0
21	A MiRNA Signature for Defining Aggressive Phenotype and Prognosis in Gliomas. PLoS ONE, 2014, 9, e108950.	1.1	60
22	MicroRNAome genome: A treasure for cancer diagnosis and therapy. Ca-A Cancer Journal for Clinicians, 2014, 64, 311-336.	157.7	428
23	Targeting the microRNA-regulating DNA damage/repair pathways in cancer. Expert Opinion on Biological Therapy, 2014, 14, 1667-1683.	1.4	36
24	Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients. Molecular Cancer, 2014, 13, 142.	7.9	40
25	Abstract 1479: A miRNA signature distinguishing low-grade and high-grade gliomas shows miR-21 and 210 as promising biomarkers of aggressive phenotype and prognosis. , 2014, , .		1
26	Abstract 1477: Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients. , 2014, , .		0
27	Abstract 2251: nrf2-keap1 axis molecular profile in small cell lung cancer cell lines. , 2014, , .		0
28	Aberrant <i>Keap1</i> methylation in breast cancer and association with clinicopathological features. Epigenetics, 2013, 8, 105-112.	1.3	77
29	Abstract 664: Aberrant KEAP1 promoter methylation is associated with disease progression in breast cancer patients treated with epirubicin/cyclophosfamide and docetaxel chemotherapy , 2013, , .		0
30	Evaluation of microRNA-10b expression as a novel predictive marker of metastases development and patients' survival in breast cancer Journal of Clinical Oncology, 2013, 31, 576-576.	0.8	0
31	Hypermethylation of the KEAP1 gene in colorectal cancer and association with disease progression Journal of Clinical Oncology, 2013, 31, e14655-e14655.	0.8	0
32	602 Frequent Epigenetic Inactivation of KEAP1 Gene in Breast Cancer. European Journal of Cancer, 2012, 48, S143.	1.3	0